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Integrated Molecular Profiling of 
Human Gastric Cancer Identifies 
DDR2 as a Potential Regulator of 
Peritoneal Dissemination
Junji Kurashige1,2, Takanori Hasegawa3, Atsushi Niida4, Keishi Sugimachi1, Niantao Deng5, 
Kosuke Mima1,2, Ryutaro Uchi1, Genta Sawada1,6, Yusuke Takahashi1,6, Hidetoshi Eguchi1, 
Masashi Inomata7, Seigo Kitano7, Takeo Fukagawa8, Mitsuru Sasako9, Hiroki Sasaki10, 
Shin Sasaki11, Masaki Mori6, Kazuyoshi Yanagihara12, Hideo Baba2, Satoru Miyano4, 
Patrick Tan5 & Koshi Mimori1
Peritoneal dissemination is the most frequent, incurable metastasis occurring in patients with 
advanced gastric cancer (GC). However, molecular mechanisms driving peritoneal dissemination still 
remain poorly understood. Here, we aimed to provide novel insights into the molecular mechanisms 
that drive the peritoneal dissemination of GC. We performed combined expression analysis with 
in vivo-selected metastatic cell lines and samples from 200 GC patients to identify driver genes of 
peritoneal dissemination. The driver-gene functions associated with GC dissemination were examined 
using a mouse xenograft model. We identified a peritoneal dissemination-associated expression 
signature, whose profile correlated with those of genes related to development, focal adhesion, and 
the extracellular matrix. Among the genes comprising the expression signature, we identified that 
discoidin-domain receptor 2 (DDR2) as a potential regulator of peritoneal dissemination. The DDR2 was 
upregulated by the loss of DNA methylation and that DDR2 knockdown reduced peritoneal metastasis 
in a xenograft model. Dasatinib, an inhibitor of the DDR2 signaling pathway, effectively suppressed 
peritoneal dissemination. DDR2 was identified as a driver gene for GC dissemination from the combined 
expression signature and can potentially serve as a novel therapeutic target for inhibiting GC peritoneal 
dissemination.
Gastric cancer (GC) is the fourth-most common human malignant disease and the second-leading cause of 
cancer-related deaths worldwide, with a particularly high incidence in East Asia1,2. The malignant potential of GC 
is characterized biologically by the dissemination of cancer cells from the primary site throughout the peritoneal 
cavity, in contrast to other tumor types that are spread hematogenously. Peritoneal dissemination is the most 
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frequent cause of death in patients with advanced GC3. However, the mechanisms underlying peritoneal dissem-
ination have not yet been specified, and advanced GC remains an incurable condition.
Previously, we established 4 cell lines with a high capability for peritoneal dissemination using 12 cycles of 
orthotropic transplantation directly into the gastric walls of nude mice and harvesting cells from ascites after 
peritoneal dissemination4,5. The phenotypes of these in vivo-selected GC cell lines resemble those in GC patients 
with peritoneal dissemination; thus, we were motivated to study the gene signatures of these cells to clarify the 
molecular mechanism of dissemination. Recent transcriptomic analyses of breast cancer, clear cell renal car-
cinoma, and colon cancer6–10 have successfully identified in vivo gene-expression signatures associated with a 
high risk of metastasis and poor overall survival. We applied computational bioinformatics analysis to determine 
the gene-expression signature related to GC peritoneal dissemination. To clarify the mechanisms of peritoneal 
dissemination in GC, we performed combined expression analyses of metastatic cell lines established from a 
peritoneal dissemination-xenograft mouse model and a clinical dataset of 200 GC patients.
Results
Establishment of a gene signature associated with peritoneal dissemination by comparison 
between resected primary tumors and in vivo-established cell lines in GC. The human parental 
cell lines HSC-44PE, HSC-39, and HSC-58 were derived from patients with gastric scirrhous cancer. The cell lines 
44As3Luc, 39As8Luc, 58As1Luc, and 58As9Luc showing high metastatic potential were derived from the parental 
cell lines following 12 cycles of direct orthotropic transplantation to the gastric walls of nude mice and gathering 
cells from the ascites (Supplementary Fig. 1a–c)11.
To identify genes that drive peritoneal dissemination, we performed expression analysis and obtained gene sets 
that were differentially activated in 4 metastatic cell lines, compared to their parent cell lines. To examine the clinical 
relevance of the in vitro-derived expression signatures, we subsequently performed extraction-of-expression mod-
ules (EEM) analysis, which tested the functionality of the input gene sets on the basis of their coherence12. Our EEM 
analysis combined with an expression dataset obtained with 200 resected GCs from a Singapore cohort13 indicated 
that the 58As9 cell line harbored a coherently expressed subset of significant size (Supplementary Fig. 2). Fifty-seven 
genes were analyzed using the EEM method, based on the expression profile observed in the 58As9 cell line. 
Considering the possibility that these 57 genes are clinically relevant, we extracted them as a gastric-dissemination 
expression signature (GDES, Fig. 1a). We found that patients harboring peritoneal metastases tended to show a 
more pronounced GDES (Fig. 1b), and patients with higher GDESs had a significantly poorer prognosis (Fig. 1c).
Correlation of module genes with focal adhesion and extracellular matrix gene sets. Next, we 
employed EEM analysis to study 1,981 gene sets that are registered with the Gene Ontology Consortium and 40 
curated Cp entries in MSigDB (http://www.broadinstitute.org/gsea/msigdb/index.jsp), for a total of 2,021 gene 
sets. Among these gene sets, 139 were significantly associated with peritoneal dissemination using a threshold of 
p < 1.0e− 6, and the module activities of these 139 gene sets were subjected to clustering analysis. By performing 
clustering analysis of the GDSE and miscellaneous gene sets, we found that the activities associated with the GDES 
positively correlated with the expression of development-related genes, focal-adhesion genes, which are funda-
mental for invasion and migration, and extracellular matrix (ECM)-related genes which are essential components 
of pre-metastatic and metastatic niches14,15 (Fig. 2a). In contrast, the activities associated with the GDES negatively 
correlated with the expression of cell cycle-related genes and genes downregulated in metastatic cell lines.
DDR2 expression was epigenetically regulated and associated with peritoneal dissemina-
tion and poor prognosis in GC. The GDES contained several ECM-related genes. Among these genes, 
we focused on a type-I collagen receptor tyrosine kinase, discoidin domain receptor 2 (DDR2), which was one 
of the most highly expressed genes in 58As9 cells, compared with the parental cell line (31-fold higher). High 
DDR2 expression significantly associated with poor prognosis and peritoneal dissemination in the GC samples 
from Singaporean and Japanese cohorts (Fig. 2b–e). We also found an inverse correlation between DDR2 mRNA 
expression and DNA promoter methylation (Fig. 3a). Low promoter methylation was also associated with peri-
toneal dissemination (Fig. 3b). We performed immunohistochemistry studies of E-cadherin and DDR2 expres-
sion on surgically resected GC and found that DDR2 expression inversely correlated with that of E-cadherin 
(Fig. 3c,d). Taken together, these data suggested that epigenetically regulated DDR2 upregulation induced the 
epithelial–mesenchymal transition (EMT), which contributes to peritoneal dissemination in GC.
Stable suppression of DDR2 reduced the cell proliferation rate, migration, and invasion and 
peritoneal dissemination. Next, we examined the involvement of DDR2 in peritoneal dissemination 
in vitro. We confirmed that DDR2 expression was elevated in 58As9 cells, compared with that in the parent 
cell line (HSC-58) by real-time quantitative reverse-transcription PCR (qRT-PCR), western blotting, and immu-
nohistochemistry (Supplementary Fig. 3a–c). To examine the function of DDR2 in 58As9 cells, we performed 
knockdown experiments using 2 independent short hairpin RNAs (shRNAs), as shown in Fig. 4a. DDR2 knock-
down did not affect cell proliferation in the absence of collagen I, but significantly suppressed cell proliferation in 
the presence of collagen I (Fig. 4b). DDR2 knockdown also attenuated the capacity of 58As9 cells for invasion and 
migration (Fig. 4c,d). We also performed knockdown experiments using the MKN7 GC cell line, which had high 
DDR2 expression, and obtained similar results (Supplementary Fig. 4a–d).
Moreover, we performed an orthotopic transplantation of DDR2-knockdown 58As9 cells in the stomach walls 
of nude mice. At 28 days post-orthotopic transplantation, we found that DDR2 knockdown reduced the number 
of disseminated metastases and tumor weights in the gastric walls (Fig. 4e–g). Based on these results, we tested 
whether DDR2 could serve as a therapeutic target for GC with peritoneal dissemination.
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Figure 1. Establishment of the peritoneal dissemination signature in gastric cancer. (a) EEM analysis 
was used to compare cell lines and clinical samples, which showed that a gene expression signature from 
the 58As9Luc cell line harbored a coherently expressed subset within the clinical gene set. Hierarchical 
clustering of primary tumor tissue from a cohort of 200 gastric cancer patients was performed using the 
top 200 gene sets (i.e. with highest expression) in 58As9 cells, compared with the parental HSC-58 cell 
line. Assuming that the 57 signature genes (right yellow box and genes list) in the coherent subset were 
clinically relevant, we extracted them as the gastric dissemination expression signature (GDES). The clinical 
characteristics of gastric cancer patients are shown at the top of the figure. Overall survival: patients that died 
following surgery are represented in the green box. Recurrence: patients showing recurrence are represented 
in the purple box. Grade: patients with a diffuse-type grade according to the Lauren classification are 
represented in the blue box. Peritoneal metastasis: patients with peritoneal tumors or who were cytology-
positive at the time of surgery are represented in the red box. Data deficiencies are represented in the gray 
box. (b) The high module activity of the GDES significantly associated with peritoneal metastasis.  
(c) Patients with high GDES module activity showed significantly poorer overall survival rates, compared  
to those with low GDES activity.
www.nature.com/scientificreports/
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Figure 2. DDR2 expression was associated with peritoneal dissemination and poor prognosis in gastric 
cancer. (a) EEM-deduced activity profiles of GDES and other gene sets were evaluated by clustering analysis. 
(b) Kaplan–Meier survival curves for the 198 patients in the Singaporean cohort, with classification based on 
DDR2 mRNA expression levels measured using a microarray. (c) DDR2 expression was significantly higher in 
gastric cancer patients with peritoneal metastasis (Singaporean cohort). (d) Kaplan–Meier survival curves for 
the 195 patients in the Japanese cohort, as measured by qRT-PCR. (e) High DDR2 expression associated with 
gastric cancer patients that developed peritoneal metastasis, as determined by performing a Pearson’s chi-square 
test (Japanese cohort).
www.nature.com/scientificreports/
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Figure 3. DDR2 overexpression was associated with DNA demethylation and epithelial-mesenchymal 
transition in gastric cancer. (a) Correlation plot between DDR2 expression and the fraction of methylation 
at the promoter region of DDR2 in 173 gastric cancer samples from the Singaporean cohort. (b) Box plot of 
the fraction of DDR2 promoter methylation between patients, with or without peritoneal metastasis.  
(c) Representative images of DDR2 and E-cadherin protein expression in gastric cancer cells. Scale bars, 
100 μm. (d) DDR2 and E-cadherin expression were inversely correlated by immunohistochemical analysis of 
76 gastric cancer samples.
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Figure 4. DDR2 inhibition reduced gastric cancer peritoneal metastasis in vitro and in vivo. (a) DDR2 
expression was suppressed in 58As9Luc cells by 2 independent shRNAs. (b) DDR2 knockdown resulted in 
lower cell proliferation on collagen I-coated 96-well plates, but did not affect cell proliferation on normal plates. 
(c,d) Effects of DDR2 on (c) cancer cell migration and (d) invasion. (e) DDR2-knockdown 58As9Luc cells 
were orthotopically transplanted into the stomach walls of nude mice. (f,g) The normalized weight of gastric 
wall tumors (f) and the number of disseminated metastatic tumors (g) at 28 days post-transplantation with 
58As9Luc cells with silenced DDR2 expression. Control, DDR2 sh#1, and sh#2: n = 8. *p < 0.05, **p < 0.01.
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Dasatinib inhibited peritoneal dissemination via Src targeting in mice. To assess the utility of 
DDR2 as a therapeutic target, we used dasatinib, an oral multi-BCR/Abl and Src family tyrosine kinase inhibitor 
that also inhibits DDR216,17. The therapeutic effects of dasatinib on peritoneal dissemination were tested in a 
xenograft mouse model. We transfected the pGL4.51 (luc2/CMV/Neo) vector into 58As9 cells to evaluate the 
in vivo effects of dasatinib with an IVIS imaging system. Both orally and intraperitoneally administered dasatinib 
effectively suppressed the peritoneal metastasis of GC (Fig. 5a–c), leading to significantly longer survival times in 
dasatinib-treated mice than those in control mice (Fig. 5d). We examined the xenografts after treatment, which 
showed reduced Src-phosphorylation levels following both oral and intraperitoneal dasatinib administration 
(Fig. 5e).
Discussion
By a combined analysis of in vitro and clinical datasets, we identified a GDES comprising genes whose expres-
sion levels are associated with gastric peritoneal dissemination. Among the genes in the GDES, our experiments 
Figure 5. Dasatinib inhibited peritoneal dissemination. (a) Mice were treated orally and intraperitoneally 
with dasatinib at 50 mg/(kg·day) or a vehicle control, beginning at day 14 post-transplantation with 58As9Luc 
cells into the gastric wall. At day 28 post-transplantation, the mice were visualized using the IVIS system. 
(b) Macroscopic images showed an enlarged peritoneal cavity and metastatic nodules by controlMock3 
and shDDR2. Arrowheads show nodules. (c) Normalized bioluminescence photon flux of disseminated 
peritoneal tumors at day 28 post-transplantation, as visualized by the IVIS system. The control and orally plus 
intraperitoneally administered dasatinib groups each contained n = 8 mice. **p < 0.01. (d) Survival curves 
showed that survival rate in dasatinib-treated mice was significantly higher (*p < 0.05) than that in control 
mice. (e) Src and Src phosphorylation, as measured by immunoblotting.
www.nature.com/scientificreports/
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showed that DDR2 was responsible for peritoneal dissemination. Moreover, we found that dasatinib, a pre-existing 
drug that inhibits DDR2 kinase function, could suppress peritoneal dissemination.
In the clinical expression dataset, the GDES significantly correlated with the ECM signature. This observation 
suggested the importance of the tumor microenvironment niche in gastric peritoneal dissemination. Stromal 
collagen fibers perpendicularly aligned to the tumor boundary can foreshadow local invasion, intravasation, and 
metastasis18,19 , possibly by inducing the EMT and promoting a local stem-cell like phenotype20–22. The ECM is a 
complex scaffolding of proteins that provides architectural support for cell and tissue organization. In turn, cells 
can adhere to collagen or other ECM molecules via different types of receptors at distant sites23,24. The current 
comprehensive analysis strongly suggested that the ECM signature was responsible for peritoneal dissemination 
and, thus, could serve as a therapeutic target for advanced GC. Collagen can bind GC cells to promote prolifera-
tion, invasion, and migration25,26.
Based on the GDES, we focused on DDR2 because it is a receptor tyrosine kinase activated by the binding of 
fibrillar collagen. Recently, it was reported that DDR2 stabilized SNAIL1 to reduce E-cadherin protein levels and 
promoted the EMT in breast cancer cells27. Recent data revealed that DDR2 mutations in lung squamous cell car-
cinoma could be therapeutically targeted by dasatinib17. In GC, DDR2 mutations exist at a rate of 3.7% (8/219; The 
Cancer Genome Atlas data), which is similar to that observed in lung squamous cell carcinoma. Considering the 
data from this database and the current study results collectively, we expect that not only DDR2 overexpression, 
but DDR2 mutations, could serve as promising therapeutic targets in GC.
Helicobacter pylori infection has been reported as a cause of gastric carcinogenesis28. H. Pylori infection carries 
cytotoxin-associated antigen A (CagA) into GC cells, after which the CagA protein binds to the Src-homology 2 
domain-containing phosphatase 2 (SHP2) domain. SHP2 acts as a positive regulator of Erk activity in GC cells. 
These findings indicate that the Src protein is necessary for the morphogenetic activity of CagA and oncogenesis 
of GC cells28,29. Interestingly, we found that DDR2, a member of the Src family, was abundantly overexpressed in 
the disseminated GC cell lines and in patients. Our results indicated that Src plays consecutive roles in carcino-
genesis and in the dissemination of GC cells. Therefore, Src should be regarded as a key molecule in the treatment 
of GC.
To suppress DDR2 activity in the xenograft mouse model of GC dissemination, we used dasatinib, which is 
approved for first-line use in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive 
acute lymphoblastic leukemia30. Recently, Yamaguchi et al. found that dasatinib suppressed the cooperation 
between scirrhous GC cells and stromal fibroblasts to form invasive structures, by screening candidate inhibitor 
molecules31. Therefore, our data suggest that DDR2 may be a promising therapeutic target for inhibiting the 
peritoneal dissemination of GC.
In conclusion, we established a peritoneal dissemination-associated gene-expression signature in GC and 
revealed that inhibiting DDR2 by dasatinib suppressed peritoneal dissemination. The results of this study provide 
novel insights into the biology of peritoneal metastasis and suggest a novel targeted therapy that may be poten-
tially used to treat GC.
Materials and Methods
Cell lines and cell culture. The human scirrhous GC cell lines HSC-44PE, HSC-39, HSC-58, 44As3, 
39As8Luc, 58As1Luc, and 58As9 were described previously4,5,11. These cell lines were cultured in RPMI 1640 
supplemented with 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY), 100 IU/mL penicillin, 
and 100 mg/mL streptomycin. 58As9 cells were transfected with the pGL4.51 [luc2/CMV/Neo] Vector (E1320 
Cloning Systems, Promega, Madison, WI) according to the manufacturer’s instructions. Stable transfectants were 
selected in Geneticin (400 μg/mL; Invitrogen, Carlsbad, CA), and bioluminescence was used to screen transfected 
clones for luciferase gene expression using the IVIS system (Xenogen, Alameda, CA). Clones expressing the lucif-
erase gene were designated as 58As9Luc cells.
Clinical GC samples and DNA and RNA extraction. Primary GC samples were obtained from 200 
patients who underwent gastric resection at the Singapore Health Services and deposited in National University 
Hospital System tissue repositories with signed, informed patient consent. Use of patient samples in this study 
was approved by the appropriate institutional research ethics review committees. Genomic DNA and RNA were 
extracted from fresh-frozen tissues using a Qiagen Genomic DNA Extraction Kit (Qiagen, Venlo, Netherlands). 
Total RNA was extracted using the Trizol reagent (Invitrogen), digested with RNase-free DNase (RQ1 DNase, 
Promega), and subsequently purified using an RNeasy Mini Kit (Qiagen).
Primary GC samples were also obtained from 195 patients who underwent gastric resection at the Oita 
Prefectural Hospital (Japan) and the Kyushu University Beppu Hospital (Japan) between 1993 and 2010. All tissue 
samples were immediately taken from the gastric resections, placed in RNA Later (Takara, Tokyo, Japan), frozen 
in liquid nitrogen, and stored at − 80 °C until RNA extraction. Total RNA was isolated from frozen tissue samples 
and cell lines using the modified acid-guanidine-phenol chloroform method, or isolated from cultured cell lines 
using an RNeasy Mini Kit (Qiagen). Moreover, 76 formalin-fixed, paraffin-embedded GC tissues from Kyushu 
University Beppu Hospital were also used in this study. All patients provided written, informed consent, and the 
study protocol was approved by the ethics committee of Kyushu University. Experiments with these samples were 
performed in accordance with the approved guidelines.
First-strand cDNA synthesis and qRT-PCR experiments. The purity and concentration of all RNA 
samples were evaluated by measuring the absorbance ratio at 260/280 nm with a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Rockland, DE). Total RNA was reverse-transcribed to cDNA with M-MLV 
Reverse Transcriptase (Invitrogen). DDR2 expression was determined using a LightCycler 480 Probes Master Kit 
(Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s instructions. Detection was achieved 
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using forward and reverse primers with sequences of 5′ -acctttggctggactctcct-3′ and 5′ -agagcattctgggaatcagg-3′, 
respectively, and Universal ProbeLibrary Probe #14 (Roche Diagnostics). All qRT-PCRs were run in a LightCycler 
480 System II (Roche Diagnostics). The relative mRNA expression levels of DDR2 were measured using the 
2−ΔΔCT method. All qRT-PCR experiments were performed in triplicate.
Gene-expression and methylation arrays. Cellular RNA-expression levels were profiled using an 
Agilent DNA microarray. Cyanine (Cy)-labeled cDNA was prepared using T7 linear amplification, after which 
it was fragmented and hybridized to an oligonucleotide microarray (Whole Human Genome 4 × 44 Agilent 
G4112F). Fluorescence intensities were obtained using an Agilent DNA microarray scanner and processed by 
quantile normalization. Methylation analysis with Infinium 450 K arrays was also performed with genomic DNA 
from cell lines. DNA methylation levels for each CpG site were computed using Genome Studio software as 
the ratio of the signal intensity for methylated DNA to the total signal intensity (methylated plus unmethylated 
DNA). The expression and methylation array data obtained with the Singaporean samples was deposited in the 
Gene Expression Omnibus database under Accession Number GSE30601.
Designed and synthesized DDR2 targeted shRNA and plasmid. The backbone plasmid pcD-
NA6.2-GW/EmGFP-miR was from the Block-iT Pol II miR RNAi Expression Vector Kit (Invitrogen). The plasmids 
pcDNA6.2-GW/EmGFP-miR-DDRshRNA (pCMV-shDDR2) containing shRNA sequences targeting the DDR2 
gene and pcDNA6.2-GW/EmGFP-miR-neg (pCMV-N) containing an unrelated insert were constructed as described 
in the manual for the Block-iT Pol II miR RNAi Expression Vector Kit. DDR2 shRNA sequences were designed 
using online software (http://www.invitrogen.com/rnai). Two double-stranded shRNAs were designed, with the fol-
lowing sequences: sh#1 top: 5′ -TGCTGAATGGAGGGTGTGCAAGTCAAGTTTTGGCCACTGACTGACTTGA 
C T T G C A C C C T C C A T T - 3 ′ ; s h # 1  b o t t o m :  5 ′ - C C T G A A T G G A G G G T G C A A G T C A A G 
T C AG T C AG T G G C C A  A A A  C T T G AC T T G C AC AC C C T C C AT T C - 3 ′ ; s h # 1  t o p :  5 ′ - T G C 
TGTCGAGTTGGACCCTTGTTCACGTTTTGGCCACTGACTGACGTGAACAAGTCCAACTCGA
-3′ ;  and sh#2 bottom: 5′-CCTGTCGAGTTGGACTTGTTCACGTCAGTCAGTGGCCAAAACGT 
GAACAAGGGTCCAACTCGAC-3′ . The unrelated insert sequence was predicted not to target any known genes.
In vitro cell proliferation, migration, and invasion assays. Cells were seeded at 3,000 cells per well 
in triplicate 96-wells coated with or without collagen I in 100 μl medium, and cell proliferation was evaluated by 
performing MTT assays using a Cell Proliferation Kit 1 (Roche Applied Science, Penzberg, Germany) according 
to the manufacturer’s instructions.
Cell-migration capacity was assessed using the BD Falcon FluoroBlok 24-Multiwell Insert System (BD 
Bioscience, San Jose, CA). Briefly, cells were seeded in the upper chamber of the 24-well plate in serum-free 
medium. The lower chamber was filled with 750 μl of medium containing 10% FBS, which acts as a chemoat-
tractant, and incubated in a humidified atmosphere (37 °C and 5% CO2). After a 48-hour incubation, the upper 
chamber was transferred into a second 24-well plate containing 500 μl/well (4 μg/ml) calcein AM in HBSS and 
incubated for an additional hour (37 °C and 5% CO2). Invasive cells that migrated through the membrane were 
evaluated in a fluorescence plate reader at excitation and emission wavelengths of 485 and 535 nm, respectively. 
Three independent experiments were performed. Similarly, cell invasion capacities were assessed using the BD 
BioCoat Tumor Invasion System, 24 Multiwell (BD Bioscience), following the same procedure used for the migra-
tion assays.
Protein detection. Immunohistochemical studies of DDR2 and E-cadherin expression were performed 
with formalin-fixed, paraffin-embedded surgical sections obtained from patients with GC. For antigen retrieval, 
tissue sections were deparaffinized and boiled in 0.01 M sodium citrate buffer in a microwave for 10 minutes at 
500 W. A rabbit polyclonal antibody against DDR2 (H-108, 1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, 
CA) and a mouse monoclonal antibody against E-cadherin (36/E-Cadherin, 1:100 dilution; BD Bioscience) were 
used as primary antibodies. All tissue sections were immunohistochemically stained using the EnVision + Dual 
Link System-HRP (Dako, Glostrup, Denmark) and were counterstained with hematoxylin. We have determined 
that the complete H score, which was semi-quantitatively calculated by summing the products of the percentage 
of cells stained at a given staining intensity (0–100) and the staining intensity score (0, no staining; 1, weak stain-
ing; 2, moderate staining; and 3, intense staining). The expression was independently evaluated by 2 of the authors 
(J. K. and K.M.) in a blinded manner in terms of clinical outcomes and other clinicopathological data.
For immunoblotting, proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis using pre-cast NuPAGE 4%–12% Bis-Tris Gels (Invitrogen), an XCell Sure Lock Mini-Cell Electrophoresis 
System (Invitrogen), and a Power PAC HC (Bio-Rad Laboratories, Hercules, CA). The resolved proteins were 
transferred to a nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen). The membranes 
were blocked with 5% iBlot (Applied Biosystems, Waltham, MA) and 0.1% Tween-20 (Bio-Rad Laboratories) 
in phosphate-buffered saline (T-PBS) for 1 hour. The membranes were then incubated with appropriate primary 
antibodies. Next, the membranes were washed twice for 5 minutes in T-PBS, incubated with an HRP-conjugated 
secondary antibody for 1 hour, and washed twice for 5 minutes in T-PBS.
Chemiluminescence detection reagents were incubated with the membranes for 1–5 minutes, followed by 
image acquisition using an Image Quant LAS500 (GE Healthcare, Little Chalfont, UK). Primary antibodies tar-
geting pan actin (Thermo Scientific, Waltham, MA) and DDR2 (H-108, Santa Cruz Biotechnology) were used 
at a dilution of 1:200. Collagen was stained using the Masson’s Trichrome Kit (Sigma-Aldrich, St. Louis, MO).
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Orthotropic and peritoneal implantation. Six-week-old female BALB/c nu/nu mice were purchased 
from Kyudo Japan, Inc.; maintained under specific pathogen-free conditions; and provided with sterile food, 
water, and cages. The ambient light was controlled to provide regular cycles of 12 hours of light and 12 hours 
of darkness. A total of 1 × 106 cancer cells were transplanted into the gastric wall of each mouse after a laparot-
omy was performed, as described previously4,5. and the all animal studies was approved by the ethics committee 
of Kyushu University and Oita University and dissected all animal procedures were performed in compliance 
with the Guidelines for the Care and Use of Experimental Animals established by the Committee for Animal 
Experimentation of Kyushu University and Oita University; these guidelines conform to the ethical standards 
required by Japanese law and also comply with the guidelines for the use of experimental animals in Japan. To 
assess the influence of DDR2 on GC dissemination, 1 × 106 cancer cells (58As9Luc control, DDR2 sh#1, or DDR2 
sh#2 cells) were transplanted into the gastric wall of each mouse. At 28 days post-transplantation, the mice were 
sacrificed and dissected, and peritoneal dissemination, liver metastasis, and ascites formation were examined. The 
number of mesentery nodules larger than 5 mm in diameter was also determined. Mice were administered dasat-
inib (50 mg/kg in 1.0 ml PBS + dimethyl sulfoxide [DMSO]) or PBS + DMSO alone by oral and intraperitoneal 
injection, thrice a week, beginning at 14 days post-transplantation. In vivo photon counting and optical imaging 
were performed to detect luciferase activity in the mice, using an IVIS system. Cancer cell engraftment into the 
gastric wall was also evaluated using the IVIS system (Supplementary Fig. 6) at 14 days post-transplantation.
EEM analysis. To identify genes that mediate peritoneal dissemination, we first compared the expression 
profiles between matching pairs of parental and derived cell lines (HSC-44PE vs. 44As3; HSC-39 vs. 39As8Luc; 
HSC-58 vs. 58As1Luc; and HSC-58 vs. 58As9) and between all parental and all derived cell lines (HSC-44PE, 
HSC-39, HSC-58: 44As3, 39As8Luc, 58As1Luc, and 58As9; Supplementary Fig. 1d). Among these 5 pairs, we 
identified gene sets that were up- or down-regulated in the derived cell line compared with the parental cell line, 
using 4 different cutoffs (top 50, 100, 200, and 400 genes). To identify gene sets of clinical relevance among the 
resulting 40 gene sets, we employed EEM analysis (https://eem.hgc.jp/), which statistically tests whether an input 
gene set has a coherently expressed subset of significant size in an expression data set of interest. EEM takes two 
types of inputs: an expression dataset of interest and a gene set library that includes gene sets used as seeds of 
modules. EEM assumes coherence as an indication of the functionality of gene sets, if a gene set have some func-
tion, the member of the gene set should be coherently expressed in the expression dataset. Under this assumption, 
EEM screens a gene set library for gene sets that have a significantly large coherent subset in the input expression 
data set. From the gene sets that passed the screening, EEM extracts coherent subsets as expression modules. 
Furthermore, EEM extracts a significantly coherent subset as an expression module and calculates the mean 
expression levels of the subset as module activities. By applying EEM to the 40 cell line-derived gene sets on the 
gastric tumor expression dataset (200 Singapore clinical set), we obtained 18 significant gene sets using a thresh-
old of p < 1.0e− 6. Among these gene sets, we selected the most significant genes in terms of overall survival rate 
and statistical significance tests, based on clinical data from the Singaporean cohort. Overall survival analysis was 
performed with respect to the overall survival rate and the number of years after the operation. A flow chart of our 
analysis is presented in Supplementary Fig. 2.
Statistics. All experiments were repeated at least 3 times. Continuous variables were expressed as the 
mean ± standard deviation. The results were statistically examined by paired Student’s, Wilcoxon’s, or Fisher’s 
tests. Overall survival curves were plotted according to the Kaplan–Meier method, and the generalized 
log-rank test was used to compare the survival curves. The findings were considered statistically significant at a 
p value < 0.05.
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